AngioDynamics (NASDAQ:ANGO – Get Free Report) and Nyxoah (NASDAQ:NYXH – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for AngioDynamics and Nyxoah, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AngioDynamics | 0 | 0 | 3 | 0 | 3.00 |
| Nyxoah | 0 | 0 | 4 | 0 | 3.00 |
AngioDynamics presently has a consensus target price of $13.00, suggesting a potential upside of 31.05%. Nyxoah has a consensus target price of $15.25, suggesting a potential upside of 34.24%. Given Nyxoah’s higher probable upside, analysts clearly believe Nyxoah is more favorable than AngioDynamics.
Risk and Volatility
Profitability
This table compares AngioDynamics and Nyxoah’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AngioDynamics | -79.38% | -7.26% | -4.78% |
| Nyxoah | -1,043.93% | -51.68% | -40.11% |
Insider & Institutional Ownership
89.4% of AngioDynamics shares are owned by institutional investors. 5.4% of AngioDynamics shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares AngioDynamics and Nyxoah”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AngioDynamics | $286.50 million | 1.40 | -$184.35 million | ($5.63) | -1.76 |
| Nyxoah | $4.52 million | 85.58 | -$46.77 million | ($1.95) | -5.83 |
Nyxoah has lower revenue, but higher earnings than AngioDynamics. Nyxoah is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
Summary
Nyxoah beats AngioDynamics on 7 of the 13 factors compared between the two stocks.
About AngioDynamics
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
